Pharma expert backs competition over price controls for cheaper medicines
In short
Murali Neelakantan said cheaper medicines will come from more competition, not from price controls. His comments came as the Supreme Court questioned gaps in medicine price regulation.
The point matters for patients, drug makers and buyers. The reporting does not say whether any rule will change.
What the reporting says
Former pharma counsel Murali Neelakantan said competition, distribution margins and government procurement deserve more focus as the Supreme Court questions gaps in medicine price regulation. The reporting does not say the court has issued a ruling, only that it is examining the issue. The immediate consequence is renewed debate over how to make medicines cheaper, while any policy change remains unknown.
Why it matters
Murali Neelakantan argued that medicine prices are better addressed through competition, distribution margins and government procurement, while the Supreme Court is questioning gaps in regulation. The reporting frames this as a policy debate rather than a decision. The affected groups are patients, pharma companies and public purchasers. No specific medicine, company, price change or court order is stated in the available reporting.